Skip to main content

Table 1 Clinical characteristics of patients

From: Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis

 

Microarray

PCR

 

RA (n = 10)

OA (n = 10)

ND (n = 10)

RA (n = 13)

OA (n = 12)

ND (n = 7)

Median age (range), years

60 (39–73)

67 (58–78)

57 (40–76)

69 (29–74)

67 (53–83)

51 (34–61)

Male/female

2/8

1/9

7/3

5/8

2/10

4/3

Median disease duration (range), years

7 (2–37)

10 (1–19)

NA

10 (4–30)

5 (1–38)

NA

Median ESR (range), mm/h

33 (12–78)

20 (10–60)

NA

32 (22–86)

11 (2–29)

NA

Median CRP (range), mg/l

22.1 (6.1–113.3)

6.4 (2–19)

NA

19 (5.9–50.8)

4.8 (0–9.3)

NA

Rheumatoid factor positive, n (range, units)

4 (47–400)

1 (29)

-

10 (15–2,450)

-

-

Patients receiving steroids, n

8

0

NA

9

0

0

All patients receiving DMARDs, n

9

0

NA

9

0

0

Patients receiving MTX

7

0

NA

6

0

0

Patients receiving NSAIDs, n

6

5

NA

8

4

0

Synovial tissue from knee

5

10

10

6

5

7

Hip

0

0

0

3

7

0

Hand synovectomy

3

0

0

3

0

0

Elbow synovectomy

2

0

0

1

0

0

  1. CRP, C-reactive protein; DMARDs, disease-modifying anti-rheumatic drugs; ESR, erythrocyte sedimentation rate; NA, not applicable; ND, normal donors; OA, osteoarthritis; RA, rheumatoid arthritis.